Engineering programmable CRISPR-based systems to precisely tune the epigenome, transcriptome, and epitranscriptome for cell fate control and next-generation genetic medicines

At EpiEdit Lab, we develop next-generation molecular technologies to interrogate, perturb and precisely regulate the mammalian epigenome, transcriptome and epitranscriptome. By combining nuclease-dead CRISPR-Cas systems with synthetic biology, RNA engineering and programmable effector modules, we build molecular tools that can control gene regulation without altering the underlying DNA sequence.

Our work uses dCas9, dCas12 and dCas13 platforms as modular building blocks, fused with regulatory proteins or recruited through RNA stem-loop binding systems, to enable predictable and spatio-temporal control of cellular functions. Through these approaches, we aim to understand how gene regulatory networks shape cell identity, lineage decisions and reprogramming outcomes. 

Beyond technology development, EpiEdit Lab is focused on applying programmable epigenome editing toward biomedical innovation, including improved lineage reprogramming strategies and future gene therapy platforms for complex and rare diseases. 

A logo that tells a scientific story

Every element of the EpiEdit Lab identity represents a key aspect of our research — from dCas9-mediated epigenome editing and guide RNA architecture to DNA targeting, PAM recognition and programmable effector domains. Science, thoughtfully woven into design.